Payment overview · 2025
General Payments
$58.34
3 reported records · 3 companies
Healthcare provider profile · identity verified
Faina Shnaydman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JAMAICA, NY · NPI 1477701068
Verified facts
What the public records show
CMS Open Payments records show Faina Shnaydman, MD received $58.34 in general payments during 2025 across 3 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 37.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Synthroid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.91 | 37.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.14 | 34.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.29 | 27.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $58.34 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 87 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 117 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
87 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
117 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 499 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 494 | 87 |
| Omeprazole | Omeprazole | 337 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 336 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 53 |
| Metformin Hcl | Metformin Hcl | 239 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 201 | 42 |
| Losartan Potassium | Losartan Potassium | 195 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 28 |
| Carvedilol | Carvedilol | 163 | 24 |
| Furosemide | Furosemide | 161 | 28 |
| Eliquis | Apixaban | 154 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 28 |
| Zenpep | Lipase/Protease/Amylase | 149 | 25 |
| Vascepa | Icosapent Ethyl | 143 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 24 |
| Dexlansoprazole Dr | Dexlansoprazole | 118 | 27 |
| Linzess | Linaclotide | 117 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 109 | 17 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 105 | 17 |
| Gabapentin | Gabapentin | 101 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 21 |
| Simvastatin | Simvastatin | 99 | 19 |
| Irbesartan | Irbesartan | 98 | 16 |
| Valsartan | Valsartan | 95 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 18 |
| Creon | Lipase/Protease/Amylase | 87 | 21 |
| Celecoxib | Celecoxib | 86 | 22 |
| Famotidine | Famotidine | 86 | 17 |
| Myrbetriq | Mirabegron | 86 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 86 | 15 |
| Telmisartan | Telmisartan | 85 | 17 |
| Synthroid | Levothyroxine Sodium | 83 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 20 |
| Montelukast Sodium | Montelukast Sodium | 82 | 13 |
| Glimepiride | Glimepiride | 79 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 16 |
| Lisinopril | Lisinopril | 71 | 13 |
| Glipizide | Glipizide | 70 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 17 |
| Januvia | Sitagliptin Phosphate | 69 | 15 |
| Metformin Hcl Er | Metformin Hcl | 69 | 14 |
| Trazodone Hcl | Trazodone Hcl | 69 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 68 | 20 |
| Tradjenta | Linagliptin | 68 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 59 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 58 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 13 |
| Tramadol Hcl | Tramadol Hcl | 57 | suppressed |
| Allopurinol | Allopurinol | 54 | 12 |
| Azithromycin | Azithromycin | 54 | 48 |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 13 |
| Atenolol | Atenolol | 53 | 15 |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Ozempic | Semaglutide | 51 | 11 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Meloxicam | Meloxicam | 46 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Crestor | Rosuvastatin Calcium | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Dexilant | Dexlansoprazole | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 36 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | 13 |
| Finasteride | Finasteride | 35 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | 11 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Febuxostat | Febuxostat | 26 | suppressed |
| Felodipine Er | Felodipine | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Belsomra | Suvorexant | 24 | suppressed |
| Clotrimazole | Clotrimazole | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 16 |
| Folic Acid | Folic Acid | 22 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Glipizide Xl | Glipizide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Xiidra | Lifitegrast | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $58.34 · 3 records | Takeda Pharmaceuticals U.S.A., Inc. | CREON, LINZESS, OTEZLA, REPATHA, TRINTELLIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error